VAN-DORZOLAMIDE-TIMOLOL SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE); TIMOLOL (TIMOLOL MALEATE)

から入手可能:

VANC PHARMACEUTICALS INC

ATCコード:

S01ED51

INN（国際名）:

TIMOLOL, COMBINATIONS

投薬量:

20MG; 5MG

医薬品形態:

SOLUTION

構図:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20MG; TIMOLOL (TIMOLOL MALEATE) 5MG

投与経路:

OPHTHALMIC

パッケージ内のユニット:

10ML

処方タイプ:

Prescription

治療領域:

BETA-ADRENERGIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0237301001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2019-08-07

製品の特徴

PRODUCT MONOGRAPH
PR
VAN-DORZOLAMIDE-TIMOLOL
Dorzolamide and timolol eye drops
BP
2
0 mg/ml, 5
m
g/ml
(as dorzolamide hydrochloride and timolol maleate)
Elevated Intraocular Pressure
Therapy
(Topical Carbonic Anhydrase Inhibitor and Topical
Beta-Adrenergic
Blocking
Agent)
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Unit-210, 2639 Viking Way,
Richmond, BC V6V 3B7
www.vancpharm.com
DATE OF PREPARATION:
27 JANUARY 2016
SUBMISSION CONTROL NO: 190791
_VAN-Dorzolamide-Timolol _
_Page 2 of 26_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE
REACTIONS....................................................................................................7
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND
STABILITY..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
.................................................................................14
PHARMACEUTICAL
INFORMATION...........................................................................